Ondrej Fischer

Olomouc, 77900, Czech Republic

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Species-origin identification of the deer in the Purtier Placenta Live Stem Cell Therapy by DNA typing.

Species-origin identification of the deer in the Purtier Placenta Live Stem Cell Therapy by DNA typing.

Journal: Forensic science international. Genetics

Published: April 24, 2026

Real-world PD-L1 testing, fi rst-line therapy for advanced NSCLC, and fi rst-line pembrolizumab monotherapy utilization and outcomes for metastatic NSCLC in the Czech Republic.

Real-world PD-L1 testing, fi rst-line therapy for advanced NSCLC, and fi rst-line pembrolizumab monotherapy utilization and outcomes for metastatic NSCLC in the Czech Republic.

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

Published: August 05, 2025

Pembrolizumab versus Pembrolizumab plus Chemotherapy in Non-small Cell Lung Cancer with High PD-L1 Expression - Multicenter Real-world Evidence Study.

Pembrolizumab versus Pembrolizumab plus Chemotherapy in Non-small Cell Lung Cancer with High PD-L1 Expression - Multicenter Real-world Evidence Study.

Journal: Journal of Cancer

Published: March 15, 2025

Myomedin variants developed for in vitro PD-L1 diagnostics in tissue samples of non-small cell lung carcinoma patients.

Myomedin variants developed for in vitro PD-L1 diagnostics in tissue samples of non-small cell lung carcinoma patients.

Journal: Journal of translational medicine

Published: February 04, 2025

Impact of PD-L1 Expression on the Overall Survival of Patients With Non-small Cell Lung Cancer Treated With Single-agent Pembrolizumab.

Impact of PD-L1 Expression on the Overall Survival of Patients With Non-small Cell Lung Cancer Treated With Single-agent Pembrolizumab.

Journal: In vivo (Athens, Greece)

Published: May 07, 2024

NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy.

NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy.

Journal: Frontiers in immunology

Published: November 21, 2023

Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer.

Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer.

Journal: Journal of cancer research and clinical oncology

Published: July 11, 2023

Comedication with corticosteroids and nonsteroidal antiphlogistics does not affect PD-L1 expression in non-small cell lung cancer.

Comedication with corticosteroids and nonsteroidal antiphlogistics does not affect PD-L1 expression in non-small cell lung cancer.

Journal: Translational cancer research

Published: February 07, 2022

Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?

Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?

Journal: Anticancer research

Published: January 20, 2022

Laboratory Parameters Associated With Inflammation Do Not Affect PD-L1 Expression in Non-small Cell Lung Cancer.

Laboratory Parameters Associated With Inflammation Do Not Affect PD-L1 Expression in Non-small Cell Lung Cancer.

Journal: Anticancer research

Published: January 20, 2022

Prognostic Value of EGFR Exon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer.

Prognostic Value of EGFR Exon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer.

Journal: Anticancer research

Published: September 20, 2021

Lung Cancer in Non-smokers in Czech Republic: Data from LUCAS Lung Cancer Clinical Registry.

Lung Cancer in Non-smokers in Czech Republic: Data from LUCAS Lung Cancer Clinical Registry.

Journal: Anticancer research

Published: August 30, 2021

Showing 1-12 of 21

Last Updated: 09/26/2026